Complement C5 C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4-Pipeline Review, H1 2016

Complement C5 C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4-Pipeline Review, H1 2016


  • Products Id :- GMDHC0073TDB
  • |
  • Pages: 96
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Pipeline Review, H1 2016', provides in depth analysis on Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted pipeline therapeutics.

The report provides comprehensive information on the Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)

The report reviews Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics and enlists all their major and minor projects

The report assesses Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Overview 9

Therapeutics Development 10

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Products under Development by Stage of Development 10

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Products under Development by Therapy Area 11

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Products under Development by Indication 12

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Products under Development by Companies 17

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Products under Development by Universities/Institutes 21

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Therapeutics Assessment 23

Assessment by Monotherapy/Combination Products 23

Assessment by Mechanism of Action 24

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Companies Involved in Therapeutics Development 29

Akari Therapeutics, Plc 29

Alexion Pharmaceuticals, Inc. 30

Alnylam Pharmaceuticals, Inc. 31

Amgen Inc. 32

Epirus Biopharmaceuticals, Inc. 33

InflaRx GmbH 34

Novartis AG 35

Noxxon Pharma AG 36

Ophthotech Corp. 37

Ra Pharmaceuticals, Inc. 38

Swedish Orphan Biovitrum AB 39

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Drug Profiles 40

AcPepA-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ALN-CC5-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ALXN-1007-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

ALXN-1210-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

ALXN-5500-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

avacincaptad pegol sodium-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Bikaciomab-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

BikajuMab-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Coversin-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

eculizumab-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

eculizumab biosimilar-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

eculizumab biosimilar-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

IFX-1-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

IFX-2-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Monoclonal Antibody for Ischemia Reperfusion Injury-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

NM-9405-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

NOXD-21-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Protein to Inhibit Complement C5 for Immunology-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

RA-101295-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

RA-101348-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

RA-101495-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

SOBI-005-Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

tesidolumab-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Dormant Projects 81

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Discontinued Products 83

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)-Featured News & Press Releases 84

Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery 84

Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG) 84

Jun 03, 2016: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data 86

Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) 86

May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barr Syndrome 87

May 19, 2016: Researchers to Present Additional Data, Including Late-Breaking Results on ALXN1007 in Patients with GI-GVHD at EHA Annual Congress 87

May 19, 2016: Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated 88

May 19, 2016: Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress 89

May 19, 2016: Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association 89

May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barr Syndrome 90

May 09, 2016: EPIRUS Announces Reprioritization of Pipeline, to focus on biosimilar product BOW080 91

Mar 31, 2016: Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin 91

Feb 16, 2016: A Statement from the Executive Officer of the Ontario Public Drug Programs on behalf of the pCPA 92

Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial 93

Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody 93

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96

List of Figures

Number of Products under Development for, H1 2016 10

Number of Products under Development by Therapy Area, H1 2016 11

Number of Products under Development by Top 10 Indication, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Assessment by Monotherapy/Combination Products, H1 2016 23

Number of Products by Stage and Mechanism of Actions, H1 2016 24

Number of Products by Routes of Administration, H1 2016 25

Number of Products by Stage and Routes of Administration, H1 2016 25

Number of Products by Molecule Types, H1 2016 27

Number of Products by Stage and Molecule Type, H1 2016 27

List of Tables

Number of Products under Development for, H1 2016 10

Number of Products under Development by Therapy Area, H1 2016 11

Number of Products under Development by Indication, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Comparative Analysis by Unknown Stage Development, H1 2016 16

Number of Products under Development by Companies, H1 2016 17

Products under Development by Companies, H1 2016 18

Products under Development by Companies, H1 2016 (Contd..1) 19

Products under Development by Companies, H1 2016 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H1 2016 21

Products under Investigation by Universities/Institutes, H1 2016 22

Assessment by Monotherapy/Combination Products, H1 2016 23

Number of Products by Stage and Mechanism of Action, H1 2016 24

Number of Products by Stage and Route of Administration, H1 2016 26

Number of Products by Stage and Molecule Type, H1 2016 28

Pipeline by Akari Therapeutics, Plc, H1 2016 29

Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 30

Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 31

Pipeline by Amgen Inc., H1 2016 32

Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 33

Pipeline by InflaRx GmbH, H1 2016 34

Pipeline by Novartis AG, H1 2016 35

Pipeline by Noxxon Pharma AG, H1 2016 36

Pipeline by Ophthotech Corp., H1 2016 37

Pipeline by Ra Pharmaceuticals, Inc., H1 2016 38

Pipeline by Swedish Orphan Biovitrum AB, H1 2016 39

Dormant Projects, H1 2016 81

Dormant Projects (Contd..1), H1 2016 82

Discontinued Products, H1 2016 83

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Akari Therapeutics, Plc

Alexion Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

Epirus Biopharmaceuticals, Inc.

InflaRx GmbH

Novartis AG

Noxxon Pharma AG

Ophthotech Corp.

Ra Pharmaceuticals, Inc.

Swedish Orphan Biovitrum AB

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Therapeutic Products under Development, Key Players in Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Therapeutics, Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Pipeline Overview, Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Pipeline, Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Pipeline Assessment

select a license

Single User License
USD 3500 INR 227150
Site License
USD 7000 INR 454300
Corporate User License
USD 10500 INR 681450

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com